Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 8/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12689512 | 1.00 | LMNA (0.44) | LMNAGAASMN1; SMN2NPSR1KMT2A | |
| SCHEMBL12693134 | 0.88 | LMNA (0.47) | LMNAGAASMN1; SMN2NPSR1KMT2A | |
| SCHEMBL15647079 | 0.82 | KMT2A (0.43) | LMNAGAASMN1; SMN2NPSR1KMT2A | |
| Hydrochloric Acid SCHEMBL4541555 | 0.81 | KMT2A (0.42) | LMNAGAASMN1; SMN2NPSR1KMT2A | |
| SCHEMBL12689367 | 0.80 | MEN1 (0.50) | SMN1; SMN2KMT2ACCR2MEN1 | |
| SCHEMBL12690371 | 0.80 | MEN1 (0.50) | SMN1; SMN2KMT2ACCR2MEN1 | |
| SCHEMBL12689385 | 0.78 | LMNA (0.41) | LMNAGAASMN1; SMN2NPSR1KMT2A | |
| SCHEMBL12689317 | 0.78 | LMNA (0.41) | LMNAGAASMN1; SMN2NPSR1KMT2A | |
| SCHEMBL12689463 | 0.78 | LMNA (0.41) | LMNAGAASMN1; SMN2NPSR1KMT2A | |
| SCHEMBL12689460 | 0.78 | LMNA (0.41) | LMNAGAASMN1; SMN2NPSR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1A | LMNA 4030/4885GAA 1394/4885SMN1; SMN2 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.